 |
|
|
| |
ACHIEVEMENT OF SVR24 DESPITE THE PRESENCE OF HCV VARIANTS RESISTANT TO FIRST-GENERATION NS5A INHIBITORS IN GENOTYPE-1 HEPATITIS C PATIENTS AFTER 8-WEEK THERAPY OF ACH-3102 IN COMBINATION WITH SOFOSBUVIR
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Dharaben Patel1, Yongsen Zhao1, Joanne Fabrycki1, Samantha Weinheimer1, Guangwei Yang1, Steven Podos1, Hetal Kocinsky1, Michael Mader1, Ed Gane2, Christian Schwabe3, David Apelian1, Mingjun Huang1 and Wengang Yang1
1Achillion Pharmaceuticals, New Haven, CT, USA; 2New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand; 3Auckland Clinical Studies Ltd, Grafton, New Zealand
|
| |
|
|
|
|
|
